Skip to main content
Top
Published in: Supportive Care in Cancer 11/2022

03-09-2022 | Nephrostomy | Research

Quality of life with tandem ureteral stents compared to percutaneous nephrostomy for malignant ureteral obstruction

Authors: Asaf Shvero, Miki Haifler, Husny Mahmud, Zohar Dotan, Harry Winkler, Nir Kleinmann

Published in: Supportive Care in Cancer | Issue 11/2022

Login to get access

Abstract

Purpose

Malignant ureteral obstruction (MUO) is treated with kidney decompression by a percutaneous nephrostomy (PCN) or internal ureteral stents. The objective of this study was to compare quality of life (QoL) with a PCN compared to tandem ureteral stents (TUS) in cases of MUO.

Methods

We reviewed the medical records of patients with MUO who were treated by PCN/TUS in our institution between June 2019 and May 2020. Patients were asked to fill out a QoL questionnaire, a tube-symptoms questionnaire, report a general health scale, and asked for a drain preference if they had experience with both drains. Scores of both groups were compared and predictors of all QoL and tube-symptoms measures were searched using multivariate analysis.

Results

Seventy-four patients with a PCN and 30 with TUS were included in the study. No statistically significant difference was found in all QoL and tube-symptoms measurements between the two drains. Type of drain was not found to be a predictor of QoL or tube-related symptoms. Eighty-four percent of patients (11/13) who have experience with both types of drains preferred TUS.

Conclusion

TUS and PCN for relief of MUO have a negative and similar effect on various areas of QoL and urinary symptoms. Most patients who had experience with both types of drains preferred TUS over PCN. In this patient population with a grim prognosis, this negative effect must be communicated to patients, and calculated against the potential benefits of drainage.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128CrossRefPubMed Ganatra AM, Loughlin KR (2005) The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174:2125–2128CrossRefPubMed
2.
go back to reference Kouba E, Wallen EM, Pruthi RS (2008) Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 180:444–450CrossRefPubMed Kouba E, Wallen EM, Pruthi RS (2008) Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 180:444–450CrossRefPubMed
3.
go back to reference Elsamra SE, Leavitt DA, Motato HA et al (2015) Stenting for malignant ureteral obstruction: tandem, metal or metal-mesh stents. Int J Urol 22:629–636CrossRefPubMed Elsamra SE, Leavitt DA, Motato HA et al (2015) Stenting for malignant ureteral obstruction: tandem, metal or metal-mesh stents. Int J Urol 22:629–636CrossRefPubMed
4.
go back to reference Liu KL, Lee BC, Ye JD et al (2019) Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. Eur Radiol 29:628–635CrossRefPubMed Liu KL, Lee BC, Ye JD et al (2019) Comparison of single and tandem ureteral stenting for malignant ureteral obstruction: a prospective study of 104 patients. Eur Radiol 29:628–635CrossRefPubMed
5.
go back to reference Haifler M, Kleinmann N, Weiss D (2021) Tandem ureteral stents drainage lowers renal pelvis pressure in malignant ureteral obstruction: experimental and computational models. J Biomech 117:110237CrossRefPubMed Haifler M, Kleinmann N, Weiss D (2021) Tandem ureteral stents drainage lowers renal pelvis pressure in malignant ureteral obstruction: experimental and computational models. J Biomech 117:110237CrossRefPubMed
6.
go back to reference Haifler M, Shvero A, Zilberman D et al (2020) Tandem ureteral stents for malignant ureteral obstruction. J Endourol 34:222–226CrossRefPubMed Haifler M, Shvero A, Zilberman D et al (2020) Tandem ureteral stents for malignant ureteral obstruction. J Endourol 34:222–226CrossRefPubMed
7.
go back to reference Alma E, Ercil H, Vuruskan E et al (2020) Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction. Support Care Cancer 28:5581–5588CrossRefPubMed Alma E, Ercil H, Vuruskan E et al (2020) Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction. Support Care Cancer 28:5581–5588CrossRefPubMed
8.
go back to reference Irani J, Siquier J, Pirès C, Lefebvre O, Doré B, Aubert J (1999) Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int 84:276–279CrossRefPubMed Irani J, Siquier J, Pirès C, Lefebvre O, Doré B, Aubert J (1999) Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int 84:276–279CrossRefPubMed
9.
go back to reference Misra S, Coker C, Richenberg J (2013) Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? Int Urol Nephrol 45:627–632CrossRefPubMed Misra S, Coker C, Richenberg J (2013) Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right? Int Urol Nephrol 45:627–632CrossRefPubMed
10.
go back to reference Monsky WL, Molloy C, Jin B et al (2013) Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Intervent Radiol 36:1355–1363CrossRefPubMedPubMedCentral Monsky WL, Molloy C, Jin B et al (2013) Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Intervent Radiol 36:1355–1363CrossRefPubMedPubMedCentral
11.
go back to reference Joshi HB, Stainthorpe A, Keeley FX, MacDonagh R, Timoney AG (2001) Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15:151–154CrossRefPubMed Joshi HB, Stainthorpe A, Keeley FX, MacDonagh R, Timoney AG (2001) Indwelling ureteral stents: evaluation of quality of life to aid outcome analysis. J Endourol 15:151–154CrossRefPubMed
12.
go back to reference Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRefPubMedPubMedCentral Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRefPubMedPubMedCentral
13.
go back to reference Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064CrossRefPubMed Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064CrossRefPubMed
14.
go back to reference Shoshany O, Erlich T, Golan S et al (2019) Ureteric stent versus percutaneous nephrostomy for acute ureteral obstruction - clinical outcome and quality of life: a bi-center prospective study. BMC Urol 19:79–85CrossRefPubMedPubMedCentral Shoshany O, Erlich T, Golan S et al (2019) Ureteric stent versus percutaneous nephrostomy for acute ureteral obstruction - clinical outcome and quality of life: a bi-center prospective study. BMC Urol 19:79–85CrossRefPubMedPubMedCentral
15.
go back to reference Joshi HB, Okeke A, Newns N, Keeley FX, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516CrossRefPubMed Joshi HB, Okeke A, Newns N, Keeley FX, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516CrossRefPubMed
16.
go back to reference Elbatanouny AM, Ragheb AM, Abdelbary AM et al (2020) Percutaneous nephrostomy versus JJ ureteric stent as the initial drainage method in kidney stone patients presenting with acute kidney injury: a prospective randomized study. Int J Urol 27:916–921CrossRefPubMed Elbatanouny AM, Ragheb AM, Abdelbary AM et al (2020) Percutaneous nephrostomy versus JJ ureteric stent as the initial drainage method in kidney stone patients presenting with acute kidney injury: a prospective randomized study. Int J Urol 27:916–921CrossRefPubMed
17.
go back to reference Xu RH, Wong ELY, Jin J, Huang H, Dong D (2021) Health-related quality of life measured using EQ-5D in patients with lymphomas. Support Care Cancer 29:2549–2560CrossRefPubMed Xu RH, Wong ELY, Jin J, Huang H, Dong D (2021) Health-related quality of life measured using EQ-5D in patients with lymphomas. Support Care Cancer 29:2549–2560CrossRefPubMed
18.
go back to reference Savin Z, Herzberg H, Ben-David R et al (2021) Long-term follow-up of yearly replaced double internal stents for extrinsic malignant ureteral obstruction. J Endourol 35:71–76CrossRefPubMed Savin Z, Herzberg H, Ben-David R et al (2021) Long-term follow-up of yearly replaced double internal stents for extrinsic malignant ureteral obstruction. J Endourol 35:71–76CrossRefPubMed
19.
go back to reference Kinjo M, Nakamura Y, Taguchi S et al (2021) Sex differences in prevalence and patient behavior regarding lower urinary tract symptoms among Japanese medical checkup examinees. Urology 151:24–30CrossRefPubMed Kinjo M, Nakamura Y, Taguchi S et al (2021) Sex differences in prevalence and patient behavior regarding lower urinary tract symptoms among Japanese medical checkup examinees. Urology 151:24–30CrossRefPubMed
Metadata
Title
Quality of life with tandem ureteral stents compared to percutaneous nephrostomy for malignant ureteral obstruction
Authors
Asaf Shvero
Miki Haifler
Husny Mahmud
Zohar Dotan
Harry Winkler
Nir Kleinmann
Publication date
03-09-2022
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2022
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-022-07354-2

Other articles of this Issue 11/2022

Supportive Care in Cancer 11/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine